Skip to main content

NRx Pharmaceuticals, Inc. (NRXP) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $3.06 (+2.68%)

Consensus Target
$2.00
Upside
-34.6%
Analysts
21
Rating
Buy(2.00)

Price Target Range

Low $2.00High $2.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy12
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Jun 30, 2022Vernon BernardinoH.C. Wainwright$2.00-34.6%

NRXP vs Sector & Market

MetricNRXPHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count21818
Target Upside-34.6%+1150.3%+14.9%
P/E Ratio-3.276.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$64M$133M$203M3
2027-12-31$479M$538M$620M1
2028-12-31$1.10B$1.10B$1.10B2
2029-12-31$1.71B$1.92B$2.21B1
2030-12-31$1.89B$2.12B$2.45B1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$0.96$1.12$1.351
2027-12-31$3.37$3.93$4.711
2028-12-31$3.18$8.42$13.662
2029-12-31$13.20$15.41$18.481
2030-12-31$12.94$15.11$18.111

Frequently Asked Questions

What is the analyst consensus for NRXP?

The consensus among 21 analysts covering NRx Pharmaceuticals, Inc. (NRXP) is Buy with an average price target of $2.00.

What is the highest price target for NRXP?

The highest price target for NRXP is $2.00, set by Vernon Bernardino at H.C. Wainwright on 2022-06-30.

What is the lowest price target for NRXP?

The lowest price target for NRXP is $2.00, set by Vernon Bernardino at H.C. Wainwright on 2022-06-30.

How many analysts cover NRXP?

21 analysts have issued ratings for NRx Pharmaceuticals, Inc. in the past 12 months.

Is NRXP a buy or sell right now?

Based on 21 analyst ratings, NRXP has a consensus rating of Buy (2.00/5) with a -34.6% upside to the consensus target of $2.00.

What are the earnings estimates for NRXP?

Analysts estimate NRXP will report EPS of $1.12 for the period ending 2026-12-31, with revenue estimated at $133M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.